Actualités

The market may be focused on temporary hurdles, but a strategic acquirer would see a unique technology at a strong price.

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter can be downloaded here. During the second quarter, AI monetization, a fragile Middle East ceasefire, and a Federal Reserve leadership transition were the significant events. All major indices ended higher, […]

Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.

Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return declining 16.1%. The recent 7 day...

ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.

Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.

Intuitive Surgical's (ISRG) competitors face unique workflow challenges and real estate issues that

The stock may be down sharply, but don't count it out -- and the lower price makes it more attractive.

Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of "Crowding Out Competitors" is strategically smart.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Oppenheimer argues Ottava and Hugo pose no near-term threat to da Vinci

With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.

Intuitive Surgical is down more than 30% this year, and one investor keeps buying anyway, convinced that a once-per-decade hardware cycle and an $8.6 billion cash fortress make the drawdown a gift rather than a warning.

Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS of $2.80 exceeding expectations by $0.30. Despite that, the stock plunged due to mounting concerns about slowing domestic procedure growth. Worldwide procedures, da Vinci and Ion […]

ISRG's premium valuation faces scrutiny as strong Q2 growth, higher margins and expanding robotic platforms support its 2026 outlook.

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]

Intuitive Surgical stock has had a difficult start to 2026, with the share price down 32.6% year to date, while the Discounted Cash Flow (DCF) intrinsic value estimate now points to a level that is broadly in line with where the market is pricing the company. The year to date decline of 32.6% raises the question of whether recent weakness is now fully reflected in the share price. Management commentary around durable demand for platforms like da Vinci 5 can support longer term cash flow...

Intuitive Surgical (NasdaqGS: ISRG) has approved amendments to its bylaws, updating shareholder voting rules, nomination processes, and procedural requirements in line with recent SEC universal proxy regulations. The revised bylaws clarify how proxy solicitations are conducted and what shareholders must disclose when putting forward director nominees or other proposals. The changes affect how investors can engage with the company on governance matters and may influence future proxy contests...

They are going through a rough patch, but it's too early to give up on them.

Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues.

Intuitive Surgical has shed a third of its value while its robotic surgery peers barely flinched, and Wall Street's most bullish analyst sees an outcome that would leave anyone who sold near the bottom regretting it.

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

Don't let their recent poor performances chase you away.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Stock Market Today: The Dow Jones index rallied 600 points Monday after Trump called off new U.S. strikes on Iran. Oil prices plunged.

8.31am: AstraZeneca talks suggest 'reduced confidence' in outlook AstraZeneca's reported talks with Bristol Myers about creating a $400 billion company appear to make "limited strategic sense for Astra and would likely be subject to antitrust scrutiny, given the overlaps of their oncology...

Intuitive Surgical (NASDAQ:ISRG) beat both top- and bottom-line consensus estimates in its fiscal Q2 2026 results, with revenue for the quarter growing 19% to $2.89 billion and adjusted EPS reaching $2.80, exceeding expectations by $0.30. However, the stock declined as investors focused on concerns surrounding slowing domestic procedure growth. Medtronic (NYSE:MDT), meanwhile, continued its turnaround […]

Intuitive Surgical (ISRG), maker of the da Vinci surgical robot, has been one of the year's most punished large-cap healthcare names, down about 37% even as revenue keeps climbing. Analysts spent months cutting targets. Then one firm broke from the pack and told investors the fear had gone too far. ...

ISRG is expanding robotic surgery beyond urology as general surgery and newer specialties gain traction, creating fresh avenues for long-term procedure growth.

Align Technology shares rise after Q2 earnings and revenues beat estimates, fueled by record Clear Aligner shipments and wider non-GAAP margins.